OP
TLSIW icon

Omni Partners’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Omni Partners’s Portfolio TLSIW Stock Details TLSIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$75K Buy
+68,231
New +$123K ﹤0.01% 232

Other funds holding TLSIW

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SCC
Spring Creek Capital Wichita, Kansas $2.53B AUM 19.59% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Omni Partners's TLSIW Position: Q1 2021 in Review

Omni Partners opened a new position in TriSalus Life Sciences Warrant (TLSIW) in Q1 2021: 68,231 shares worth $75K. The stake represents ﹤0.01% of the portfolio and ranks #232 among its holdings.

26 funds tracked by Wall St. Rank hold TLSIW as of Q1 2021.

  • Omni Partners held 68,231 shares of TriSalus Life Sciences Warrant worth $75K as of Q1 2021.
  • TriSalus Life Sciences Warrant was a new Omni Partners position in Q1 2021.
  • TriSalus Life Sciences Warrant made up ﹤0.01% of Omni Partners's portfolio in Q1 2021, its #232 holding.
  • 26 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q1 2021.

Based on Omni Partners's 13F filing for Q1 2021, filed 17 May 2021.